Anti-VEGF antibodies

Details Anti-VEGF antibodies Anti-VEGF antibodies

2011-03-22

2011-03-22

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S134100, C424S141100, C424S142100, C424S145100, C435S007100, C530S387100, C530S387300, C530S388100, C530S388150, C530S388240, C530S391300

Reexamination Certificate

active

07910098

ABSTRACT:
The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.

REFERENCES:
patent: 4774378 (1988-09-01), Faure et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5498530 (1996-03-01), Schatz et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5688666 (1997-11-01), Bass et al.
patent: 5723286 (1998-03-01), Dower et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5750373 (1998-05-01), Garrard et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5837242 (1998-11-01), Holliger et al.
patent: 5928641 (1999-07-01), Seon et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6172197 (2001-01-01), McCafferty et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6416758 (2002-07-01), Thorpe et al.
patent: 6703020 (2004-03-01), Thorpe et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7208582 (2007-04-01), Rosen et al.
patent: 7691977 (2010-04-01), Fuh et al.
patent: 2005/0186208 (2005-08-01), Fyfe et al.
patent: 2006/0280747 (2006-12-01), Fuh et al.
patent: 2007/0020267 (2007-01-01), Fuh et al.
patent: 2007/0141065 (2007-06-01), Fuh et al.
patent: 2008/0248033 (2008-10-01), Ferrara et al.
patent: 2 019 559 (1990-12-01), None
patent: 0 368 684 (2004-09-01), None
patent: WO 93/11161 (1993-06-01), None
patent: WO 95/27062 (1995-10-01), None
patent: WO 97/44453 (1997-11-01), None
patent: WO 97/45450 (1997-12-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 00/34337 (2000-06-01), None
patent: WO 2005/012359 (2005-02-01), None
patent: WO 2005/044853 (2005-05-01), None
patent: WO 2005/123104 (2005-12-01), None
Rudikoff et al, Proc Natl Acad Sci USA 79: 1979-1983, 1982.
Barrios et al, J Molecular Recognition 17: 332-338, 2004.
MacCallum et al, J Mol. Biol 262: 732-745, 1996.
Wu et al, J. Mol. Biol. 294: 151-162, 1999.
Pini et al., “Design and Use of a Phage Display Library: Human Antibodies with Subnanomolar Affinity Against a Marker of Angiogenesis Eluted From a Two-Dimensional Gel,”J. Biol. Chem. 273:21769-21776 (1998).
Adamis et al., “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate,”Arch. Ophthalmol. 114: 66-71 (1996).
Aiello et al., “Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders,”N. Engl. J. Med. 331: 1480-1487 (1994).
Barbas et al., “In vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity,”Proc. Natl. Acad. Sci. USA91: 3809-3813 (1994).
Barbas et al., “Selection and Evolution of High-Affinity Human Anti-Viral Antibodies,”Tibtech. 14: 230-234 (1996).
Barrios et al., “Length of the Antibody Heavy Chain Complementarity Determining Region 3 as a Specificity-Determining Factor,”J. Mol. Recongnit. 17: 332-338 (2004).
Bass et al., “Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties,”Proteins8: 309-314 (1990).
Beiboer et al., “Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics Yet Structural Divergence Between the Original Murine Antibody and Its Human Equivalent,”J. Mol. Biol. 296: 833-849 (2000).
Berkman et al., “Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms,”J. Clin. Invest. 91: 153-159 (1993).
Borgström et al., “Complete Inhibition of Angiogenisis and Growth of Microtumors by Anti-Vascular Endothelial Growth Factor Neutralizing Antibody: Novel Concepts of Angiostatic Therapy from Intravital Videomicroscopy,”Cancer Res. 56: 4032-4039 (1996).
Brekken et al., “Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium,”Cancer Res. 58: 1952-1959 (1998).
Brown et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of the Gastrointestinal Tract,”Cancer Res. 53: 4727-4735 (1993).
Brown et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Breast Cancer,”Hum. Pathol. 26: 86-91 (1995).
Carmeliet et al., “Abnormal Blood Vessel Development and Lethality in Embryos Lacking a Single VEGF Allele,”Nature380: 435-439 (1996).
Carmeliet et al., “Angiogenesis in Cancer and Other Diseases,”Nature407: 249-257 (2000).
Carter et al., “High Level ofEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment,”Biotechnology10: 163-167 (1992).
Carter et al., “Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy,”Proc. Natl. Acad. Sci. USA89: 4285-4289 (1992).
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-Matured Fab in Complex with Antigen,”J. Mol. Biol. 293: 865-881 (1999).
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”J. Mol. Biol. 196: 901-917 (1987).
Christinger et al., “Crystallization of the Receptor Binding Domain of Vascular Endothelial Growth Factor,”Proteins26: 353-357 (1996).
Clackson et al., “Making Antibody Fragments Using Phage Display Libraries,”Nature352: 624-628 (1991).
Cunningham et al., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,”Science244: 1081-1085 (1989).
de Wildt et al., “Antibody Arrays for High-Throughput Screening of Antibody-Antigen Interactions,”Nat. Biotechnol. 18: 989-994 (2000).
Deng et al., “Selection of Antibody Single-Chain Variable Fragments with Improved Carbohydrate Binding by Phage Display,”J. Biol. Chem. 269: 9533-9538 (1994).
Deshayes et al., “Rapid Identification of Small Binding Motifs with High-Throughput Phage Display: Discovery of Peptidic Antagonists of IGF-1 Function,”Chem. Biol. 9: 495-505 (2002).
Dvorak et al., “Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis,”Am. J. Pathol. 146: 1029-1039 (1995).
Ellis et al., “Surgical Resection After Downsizing of Colorectal Liver Metastasis in the Era of Bevacizumb,”J. Clin. Oncol. 23: 4853-4855 (2005).
Ferrara et al., “Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins,”Endocr. Rev. 13: 18-32 (1992).
Ferrara et al., “Heterozygous Embryonic Lethality Induced by Targeted Inactivation of the VEGF Gene,”Nature380: 439-442 (1996).
Ferrara et al., “The Biology of Vascular Endothelial Growth Factor,”Endocr. Rev. 18: 4-25 (1997).
Ferrara et al., “Vascular Endothelial Growth Factor is Essential for Corpus Luteum Angiogenesis,”Nat. Med. 4: 336-340 (1998).
Ferrara et al., “Clinical Applications of Angiogenic Growth Factors and Their Inhibitors,”Nat. Med. 5: 1359-1364 (1999).
Ferrara et al., “Molecular and Biological Properties of Vascular Endothelial Growth Factor,”J. Mol. Med. 77: 527-543 (1999).
Ferrara et al., “Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration,”Annu. Rev. Med. 58: 491-504 (2007).
Folkman et al., “Angiogenic Factors,”Science235: 442-447 (1987).
Fuh et al., “Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab,”J. Biol. Chem. 281: 6625-6631 (2006).
Garrard et al., “Selection of an Anti-IGF-1 Fab from A Phage Library Created by Mutagenesi

Affiliated with

Also associated with

Rating

Anti-VEGF antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-VEGF antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-VEGF antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2632886